TY  - JOUR
AU  - Entrenas-Costa, Luis Manuel
AU  - Casas-Maldonado, Francisco
AU  - Soto-Campos, Jose Gregorio
AU  - Padilla-Galo, Alicia
AU  - Levy, Alberto
AU  - Alvarez Gutierrez, Francisco Javier
AU  - Gomez-Bastero-Fernandez, Ana P
AU  - Morales-Garcia, Concepcion
AU  - Gallego-Dominguez, Rocio
AU  - Villegas-Sanchez, Gustavo
AU  - Mateos-Caballero, Luis
AU  - Pereira-Vega, Antonio
AU  - Garcia-Polo, Cayo
AU  - Perez-Chica, Gerardo
AU  - Martin-Villasclaras, Juan Jose
PY  - 2019
DO  - 10.1007/s41669-019-0117-4
UR  - https://hdl.handle.net/10668/25494
T2  - PharmacoEconomics - open
AB  - Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes...
LA  - en
PB  - Springer
KW  - Omalizumab
KW  - Health Expenditures
KW  - Spain
KW  - Pulmonary Medicine
KW  - Cost-Benefit Analysis
KW  - Retrospective Studies
KW  - Asthma
KW  - Antibodies, Monoclonal, Humanized
KW  - Rhinitis
TI  - Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.
TY  - research article
VL  - 3
ER  -